Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes

Total Page:16

File Type:pdf, Size:1020Kb

Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes 0090-9556/09/3712-2314–2322$20.00 DRUG METABOLISM AND DISPOSITION Vol. 37, No. 12 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 28944/3537714 DMD 37:2314–2322, 2009 Printed in U.S.A. Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes Jennifer Q. Dong and Philip C. Smith Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Seattle, Washington (J.Q.D.); and Eschelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.C.S.) Received June 15, 2009; accepted September 17, 2009 ABSTRACT: Benoxaprofen (BNX), a nonsteroidal anti-inflammatory drug the hypothesis that part of the covalent binding of all three NSAIDs (NSAID) that was withdrawn because of hepatotoxicity, is more to hepatic proteins is acyl glucuronide-dependent. Moreover, the- toxic than its structural analog flunoxaprofen (FLX) in humans and ses studies confirmed the feasibility of using sandwich-cultured rats. Acyl glucuronides have been hypothesized to be reactive rat hepatocytes for studying glucuronidation and covalent binding metabolites and may be associated with toxicity. Both time- and to hepatocellular proteins. These studies also showed that these in concentration-dependent glucuronidation and covalent binding of vitro methods can be applied using human tissues for the study of BNX, FLX, and ibuprofen (IBP) were determined by exposing sand- acyl glucuronide reactivity. More BNX-protein adduct was formed wich-cultured rat hepatocytes to each NSAID. The levels of gluc- in sandwich-cultured human hepatocytes than FLX-protein ad- uronide and covalent protein adduct measured in cells followed duct, which not only agreed with its relative toxicity in humans but the order BNX > FLX > IBP. These results indicate that 1) BNX- also was consistent with the in vitro findings using rat hepatocyte glucuronide (G) is more reactive than FLX-G, and 2) IBP-G is the cultures. These data support the use of sandwich-cultured human least reactive metabolite, which support previous in vivo studies in hepatocytes as an in vitro screening model of acyl glucuronide rats. The proportional increases of protein adduct formation for exposure and reactivity. BNX, FLX, and IBP as acyl glucuronidation increased also support Many types of acidic drugs form acyl glucuronides, and other individual glucuronides for each drug candidate, a process that can be xenobiotics are metabolized to carboxylic acids (Phase I metabolites), tedious and costly. In addition, hepatic tissue proteins are not present which subsequently undergo Phase II conjugation to form acyl gluc- in the incubation, which makes it less likely to correlate covalent uronides. Often such a glucuronide conjugate constitutes the major protein binding with hepatotoxicity. In vitro models involving hepatic metabolite. The major site of conjugation for most compounds in materials, including liver homogenates, microsomal subcellular prep- humans is believed to be the liver. Modification of critical hepatic aration, and isolated hepatocyte suspensions and cultures, offer many proteins by covalent binding of acidic drugs through reactive acyl advantages over in vitro incubation with model proteins. Not only are glucuronides may provide a basis for direct hepatocyte toxicity or hepatic tissue proteins present, but UDP glucuronosyltransferase immune-mediated adverse reactions (Gillette, 1974; Faed, 1984; (UGT) activities that catalyze the glucuronidation reactions are also Boelsterli, 2002; Bailey and Dickinson, 2003). maintained. However, membrane transport functions are lost or not Some pharmaceutical companies have been conducting in vitro well maintained in isolated hepatocytes or even primary hepatocyte experiments by incubating acyl glucuronides with model proteins or cultures. Although the intact animal model represents undisturbed peptides (Wang et al., 2004) to determine their reactivity, and hence hepatic physiology, high-throughput screenings using in vivo studies possibly predict the relative extent of covalent protein binding in vivo are not very practical. Moreover, extrapolation of animal data to in humans. This method requires chemical synthesis or biosynthesis of humans is often questionable, especially for drug metabolism. We propose that hepatocyte culture with a “sandwich” configura- tion would be a good model for estimating covalent binding to hepatic This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant GM61188]. tissue proteins in vivo. Hepatocyte monolayer is cultured between two Article, publication date, and citation information can be found at layers of Matrigel, a matrix material resembling the mammalian http://dmd.aspetjournals.org. cellular basement membrane, and this has been shown to prolong cell doi:10.1124/dmd.109.028944. viability and has better preservation of liver-specific protein synthesis ABBREVIATIONS: UGT, UDP glucuronosyltransferase; BNX, benoxaprofen; FLX, flunoxaprofen; IBP, ibuprofen; HPLC, high-performance liquid chromatography; PBS, phosphate-buffered saline; SKF-525A, proadifen hydrochloride; LDH, lactate dehydrogenase; ABT, 1-aminobenzotriazole; DMEM, Dulbecco’s modified Eagle’s medium; MCM, modified Chee’s medium; PMSF, phenylmethylsulfonyl fluoride; PH, 1,7-phenanthroline; BNX-G, benoxaprofen glucuronide; FLX-G, flunoxaprofen glucuronide; IBP-G, ibuprofen glucuronide; P450, cytochrome P450; NSAID, nonste- roidal anti-inflammatory drug. 2314 ACYL GLUCURONIDE AND COVALENT BINDING IN HEPATOCYTE CULTURES 2315 Materials and Methods O O R 1 Materials. Rac-BNX was extracted and purified from tablets of Oraflex N HO previously marketed by Eli Lilly & Co. (Indianapolis, IL). [Analysis calculated CH3 for BNX (C16H12ClNO3): C, 63.69; H, 4.01; N, 4.64; Cl, 11.75; O, 15.91. Found: C, 63.05; H, 4.31; N, 4.71; Cl, 11.68; O, 16.25.] The purity of BNX (Ͼ99%) was confirmed based on elemental analysis and analytical high- performance liquid chromatography (HPLC) using UV detection at wave- FIG. 1. Structures of BNX and FLX. BNX was marketed as the racemate; FLX was length of 210 nm. S-FLX, the marketed form, was contributed by Dr. A. marketed as the S-isomer. Forgione (Ravizza Laboratories, Milan, Italy) and was determined to be pure (Ͼ98%) based on HPLC with UV detection. IBP, Triton X-100, EDTA, than primary hepatocytes maintained under conventional culture con- glycerol, glycine, phosphate-buffered saline (PBS), borneol, SKF-525A, lac- ditions (Dunn et al., 1989, 1991). This model system uses biologically tate dehydrogenase (LDH) kit, Percoll, Hanks’ balanced salt solution, and 3 relevant matrix components and therefore is more close to the native dexamethasone were obtained from Sigma-Aldrich (St. Louis, MO). [ H]IBP architecture of the hepatocyte environment. A unique feature of this (1 Ci/mmol) was purchased from ICN (currently Valeant Pharmaceuticals, Costa Mesa, CA). 1,7-Phenanthroline was purchased from Aldrich Chemical sandwiched culture of hepatocytes is the formation of functional bile Co. (Milwaukee, WI). 1-Aminobenzotriazole (ABT) was a gift from Dr. J. canalicular networks formed with rat hepatocytes. In addition, the Mathews at Triangle Research Institute (Research Triangle Park, NC). Proto- normal polarized distribution of several different classes of function- gel, ammonium sulfate, TEMED, dithiothreitol, bromophenol blue, and Tris ally active canalicular transport systems, such as multidrug-resistant were purchased from Bio-Rad Laboratories (Hercules, CA). Collagenase was protein 2, is also re-established in this configuration (LeCluyse et al., obtained from Worthington Biochemicals (Freehold, NJ). Dulbecco’s modified 1994). It has been reported that the hepatobiliary transport of reactive Eagle’s medium (DMEM), modified Chee’s medium (MCM), fetal calf serum, diclofenac glucuronide via multidrug-resistant protein 2 is critical for and insulin were purchased from Invitrogen (Carlsbad, CA). Rat tail collagen diclofenac covalent binding to proteins in the biliary tree (Seitz et al., (type I) was obtained from Collaborative Research (Bedford, MA). Matrigel was purchased from Thermo Fisher Scientific (Waltham, MA). Methanol and 1998). In addition to being a much more biologically relevant in vitro acetonitrile were HPLC grade from Mallinckrodt Baker, Inc. (Phillipsburg, model in terms of morphology and biochemical properties, this sand- NJ). All of the other chemicals used were of reagent grade. Male Sprague- wiched hepatocyte culture system also maintains a better functional Dawley rats (250–350 g) were supplied by Harlan (Indianapolis, IN). Exper- enzyme/transport system than microsomes, with which the hepato- iments were approved by the university’s animal care committee. Human liver cytes can generate metabolites such as acyl glucuronides. Further- microsomal preparations were obtained from BD Gentest (Woburn, MA). more, the availability of sandwiched human hepatocyte cultures will Isolation and Culture of Rat Hepatocytes. Plastic culture dishes (60 mm) allow in vitro evaluation of covalent binding in hepatocytes using were precoated with rat tail collagen, type I (0.1 ml/dish, 1.5 mg/ml), in a human tissues. This is essential for studies of compounds that are gelled state at least 1 day before hepatocyte harvest. To obtain a gelled potentially toxic to humans because direct detection of acyl gluc- collagen substratum, neutralized collagen type I was prepared
Recommended publications
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • Effects of Clofibric Acid on the Biliary Excretion of Benoxaprofen
    ORIGINAL ARTICLES Clinical Pharmaceutics Laboratory, Department of Pharmacy and Health Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan Effects of clofibric acid on the biliary excretion of benoxaprofen glucuronide and taurine conjugate in rats K. Okada, H. Kanoh, K. Mohri Received March 8, 2011, accepted April 15, 2011 Prof. Kiminori Mohri, Clinical Pharmaceutics Laboratory, Department of Pharmacy and Health Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose-shi, Tokyo 204-8588, Japan [email protected] Pharmazie 66: 777–783 (2011) doi: 10.1691/ph.2011.1031 Benoxaprofen (BOP) is a 2-methyl propionic acid derivative with anti-inflammatory activity. BOP has an asymmetric carbon, and receives chiral inversion from R to S in vivo. BOP is metabolized to glucuronide (BOP-G) and taurine conjugate (BOP-T). The configuration of BOP-G is mainly S, and that of BOP-T is R. Chiral inversion of R to S of the propionic acid moiety and amino acid conjugation of carboxyl compounds proceed via an acyl CoA intermediate. It is known that fibrates, used in hyperlipidemia, induce acyl CoA synthetase and increase CoA concentration. We administered racemic BOP (10 mg/kg body weight) to rats (CFA+ ) pre-administered clofibric acid (CFA, 280 mg/kg/day), and studied BOP, BOP-G, and BOP-T enantiomer concentrations in plasma and bile up to 12 h after administration. The findings were compared with those in rats (CFA-) that had not received CFA. Furthermore, we studied the amounts of BOP-G enantiomer produced by glucuronidation in vitro using microsomes pretreated with CFA.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Wo 2009/139817 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 19 November 2009 (19.11.2009) WO 2009/139817 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/4709 (2006.01) C07D 405/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) Number: International Application CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, PCT/US2009/002391 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 15 April 2009 (15.04.2009) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (25) Filing Language: English NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (26) Publication Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/045,142 15 April 2008 (15.04.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): SAR- GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, CODE CORPORATION [US/US]; Suite 505, 343 San- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, some Street, San Francisco, CA 94104 (US).
    [Show full text]
  • Pharmaceutical Co-Crystal Compositions of Celecoxib
    (19) & (11) EP 2 339 328 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.06.2011 Bulletin 2011/26 G01N 21/27 (2006.01) G01N 25/08 (2006.01) C07B 63/00 (2006.01) A61K 31/415 (2006.01) (2006.01) (2006.01) (21) Application number: 10193736.5 C07B 63/04 C07D 231/12 (22) Date of filing: 24.12.2003 (84) Designated Contracting States: • Remenar, Julius AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Framingham, MA 01701 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Peterson, Matthew Hopkinton, MA 01748 (US) (30) Priority: 30.12.2002 US 437516 P • Almarsson, Orn 21.01.2003 US 441335 P Shrewsbury, MA 01545 (US) 28.02.2003 US 451213 P • Guzman, Hector 18.03.2003 US 456027 P Boston, MA 02118 (US) 21.03.2003 US 456608 P • Chen, Hongming 01.04.2003 US 459501 P Acton, MA 01720 (US) 20.06.2003 US 601092 • Oliveira, Mark 11.07.2003 US 486713 P Bedford, MA 01730 (US) 11.07.2003 US 487064 P 11.09.2003 US 660202 (74) Representative: Daniels, Jeffrey Nicholas 20.06.2003 PCT/US03/19574 Page White & Farrer 04.09.2003 PCT/US03/27772 Bedford House 16.09.2003 PCT/US03/28982 John Street London WC1N 2BF (GB) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 03808567.6 / 1 579 198 •Claims filed after the date of filing of the application/ after the date of receipt of the divisional application (71) Applicant: Transform Pharmaceuticals, Inc.
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Synthesis and Evaluation of Mutual Azo Prodrug of 5-Aminosalicylic Acid Linked to 2-Phenylbenzoxazole-2-Yl-5-Acetic Acid in Ulcerative Colitis
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis Jamal A Jilani1 Abstract: In this study, the syntheses of 4-aminophenylbenzoxazol-2-yl-5-acetic acid, Maha Shomaf2 (an analogue of a known nonsteroidal anti-inflammatory drug [NSAID]) and 5-[4-(benzo- Karem H Alzoubi3 xazol-2-yl-5-acetic acid)phenylazo]-2-hydroxybenzoic acid (a novel mutual azo prodrug of 5-aminosalicylic acid [5-ASA]) are reported. The structures of the synthesized compounds 1Department of Medicinal Chemistry 1 and Pharmacognosy, Jordan University were confirmed using infrared (IR), hydrogen-1 nuclear magnetic resonance ( H NMR), and of Science and Technology, Irbid, mass spectrometry (MS) spectroscopy. Incubation of the azo compound with rat cecal contents 2 Jordan; Department of Pathology, demonstrated the susceptibility of the prepared azo prodrug to bacterial azoreductase enzyme. Jordan University, Amman, Jordan; 3Department of Clinical Pharmacy, The azo compound and the 4-aminophenylbenzoxazol-2-yl-5-acetic acid were evaluated for Jordan University of Science and inflammatory bowel diseases, in trinitrobenzenesulfonic acid (TNB)-induced colitis in rats. Technology, Irbid, Jordan The synthesized diazo compound and the 4-aminophenylbenzoxazol-2-yl-5-acetic acid were found to be as effective as 5-aminosalicylic acid for ulcerative colitis.
    [Show full text]
  • Risk Assessment of Reactive Metabolites in Drug Discovery: a Focus on Acyl Glucuronides and Acyl-Coa Thioesters
    Risk Assessment of Reactive Metabolites in Drug Discovery: A Focus on Acyl Glucuronides and Acyl-CoA Thioesters The Delaware Valley Drug Metabolism Discussion Group 2017 Rozman Symposium HUMAN BIOTRANSFORMATION: THROUGH THE MIST Langhorne, PA, June 13, 2017 Mark Grillo, PhD Drug Metabolism & Pharmacokinetics MyoKardia South San Francisco, CA [email protected] CommercializationDrug Process Discovery Overview & Development Therapeutic Area/Disease Lead Selection & Product Strategy Market Readiness & Launch / Post-Launch Opportunity Assessment Pre-clinical Testing Development Regulatory Approval Lifecycle Management Hit-to- Lead Post- Discovery Screen Pre-clinical Phase 1 Phase 2 Phase 3 Filing Launch Lead Optimization Launch Preclinical Pharmacokinetics & Drug Metabolism Assays Target Selection & Validation Lead compound Selection Discovery Screen Hit-to-Lead Lead Optimization Optimize Pharmacokinetics Characterize Preclinical Candidate Liver microsomal stability Intrinsic clearance Membrane permeability Excretion balance Efflux/transport assays Definitive metabolite ID Plasma stability Higher species PK Rat PK Human PK prediction Protein binding Assess DDI Potential Blood to plasma ratio Competitive CYP IC50 Early DDI Assessment Time-dependent CYP inhibition Enzyme induction PXR activation Hepatocyte induction CYP inhibition CYP reaction phenotyping Detection and Assessment of Chemically-Reactive Metabolites 2 Circumstantial Evidence Links Reactive Metabolites to Adverse Drug Reactions • Toxicity is a frequent cause of drug withdrawal
    [Show full text]